ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Minimum clinical protocol for neurologic follow-up in Gaucher disease

Minimum clinical protocol for neurologic follow-up in Gaucher disease
1. Clinical examination
Neurologic examination: Every 3 months during year 1, every 6 months thereafter. Neurologic examination to include scoring as defined in the Severity Scoring Tool for NGD[1] to monitor changes. In adolescent and adult patients who are stable, neurologic examination once a year may be sufficient.
If eye movements were considered to be normal at the time of initial assessment or if the result was equivocal (often the case with very young or sick children), such testing should be repeated.
Additional neuroophthalmological investigation: Only if clinically indicated (eg, development of sixth-nerve palsy).
Peripheral hearing (audiometry or electroacoustical emissions depending on age, as stated above): Evaluating trends every 2 or 3 years.
2. Brain imaging
Only if clinically indicated. The risk of anesthesia should be considered. An exception to this may be made in patients who have the D409H allele. Such patients may be at risk of hydrocephalus[2,3] and may therefore need to be scanned on a regular basis.
3. Neurophysiology
EEG: Should be performed if clinically indicated (eg, presence of seizures, baseline study looking for background slowing in suspected GD3). If myoclonus is suspected, telemetry may be needed.
Nerve conduction velocity: Only if clinically indicated with reported symptoms of tingling, numbness, or pins and needles.
4. Neuropsychometry
Annual assessments are probably not necessary as they are time consuming. We suggest the following: Assessment at school entry, then at transition from primary to secondary school, then when transitioning to college/adult education. Age-appropriate scales should be used.
NGD: neuronopathic Gaucher disease; EEG: electroencephalography; GD3: type 3 Gaucher disease.
References:
  1. Davies EH, Surtees R, DeVile C, et al. A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis 2007b; 30:768.
  2. Inui K, Yanagihara K, Otani K, et al. A new variant neuropathic type of Gaucher's disease characterized by hydrocephalus, corneal opacities, deformed toes, and fibrous thickening of spleen and liver capsules. J Pediatr 2001; 138:137.
  3. Shiihara T, Oka A, Suzaki I, et al. Communicating hydrocephalus in a patient with Gauchers disease type 3. Pediatr Neurol 2000; 22:234.
Adapted from: Vellodi A, Tylki-Szymanska A, Davies EH, et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis 2009; 32:660, with kind permission from Springer Science + Business Media B.V. Copyright © 2009.
Graphic 64752 Version 12.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟